The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae
Launched by NATIONAL UNIVERSITY OF MALAYSIA · Apr 14, 2020
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
A randomised control study involving primigravida in labour who require pitocin augmentation. Once patient require augmentation, patient will be randomised into intervention group (receiving intravenous buscopan 1ml or 20mg) and control group (intravenous normal saline 1ml). Both fluids are colourless. The primary outcome is duration from augmentation to os fully. The secondary outcome are to look on mode of delivery particularly any caesarean section due to failure to poor progress, maternal side effect (dry mouth and tachycardia) and baby outcome (apgar score and neonatal intensive care u...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Primigravida
- • Vertex presentation
- • Term gestation (37-41w)
- • Active phase of labor (4cm with regular contraction at least 2:10)
- • Spontaneous labor
- • Oxytocin augmentation
- • Maternal height ≥150cm
- Exclusion Criteria:
- • Multiple pregnancies
- • Previous uterine surgery
- • Hypertensive disease in pregnancy
- • Gestational diabetes on treatment
- • Clinical estimation of fetal weight \>3.8kg
- • Induction of labor
- • Meconium stained liquor
- • Allergy to hyoscine
- • Medical contraindication to hyoscine (i.e Myasthenia gravis, glaucoma, megacolon)
About National University Of Malaysia
The National University of Malaysia (Universiti Kebangsaan Malaysia, UKM) is a prestigious institution dedicated to advancing medical research and clinical trials that contribute significantly to the fields of healthcare and biomedical sciences. As a leading academic and research university, UKM is committed to fostering innovation and excellence in clinical research, promoting collaboration among multidisciplinary teams, and enhancing the quality of patient care. The university's robust infrastructure and experienced research faculty facilitate rigorous clinical trials aimed at addressing critical health challenges, thereby improving health outcomes both locally and globally. Through its dedication to ethical research practices and adherence to regulatory standards, UKM strives to enhance the understanding of diseases and develop effective interventions that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cheras, Kuala Lumpur, Malaysia
Patients applied
Trial Officials
Aida Hani Mohd Kalok
Principal Investigator
National University Malaysia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials